Comprehensive and Automated Linear Interaction Energy Based Binding-Affinity Prediction for Multifarious Cytochrome P450 Aromatase Inhibitors

Cytochrome P450 aromatase (CYP19A1) plays a key role in the development of estrogen dependent breast cancer, and aromatase inhibitors have been at the front line of treatment for the past three decades. The development of potent, selective and safer inhibitors is ongoing with in silico screening methods playing a more prominent role in the search for promising lead compounds in bioactivity-relevant chemical space. Here we present a set of comprehensive binding affinity prediction models for CYP19A1 using our automated Linear Interaction Energy (LIE) based workflow on a set of 132 putative and structurally diverse aromatase inhibitors obtained from a typical industrial screening study. We extended the workflow with machine learning methods to automatically cluster training and test compounds in order to maximize the number of explained compounds in one or more predictive LIE models. The method uses protein–ligand interaction profiles obtained from Molecular Dynamics (MD) trajectories to help model search and define the applicability domain of the resolved models. Our method was successful in accounting for 86% of the data set in 3 robust models that show high correlation between calculated and observed values for ligand-binding free energies (RMSE < 2.5 kJ mol–1), with good cross-validation statistics.

[1]  Martin Almlöf,et al.  Free energy calculations and ligand binding. , 2003, Advances in protein chemistry.

[2]  R. W. Hockney,et al.  Time integration in particle models , 1987 .

[3]  K. J. Ryan Conversion of androstenedione to estrone by placental microsomes. , 1958, Biochimica et biophysica acta.

[4]  Luigi Capoferri,et al.  Improving the iterative Linear Interaction Energy approach using automated recognition of configurational transitions , 2016, Journal of Molecular Modeling.

[5]  A. Bhatnagar,et al.  Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. , 1996, Acta oncologica.

[6]  Chris Oostenbrink,et al.  Computational Prediction of Binding Affinity for CYP1A2-Ligand Complexes Using Empirical Free Energy Calculations , 2010, Drug Metabolism and Disposition.

[7]  Vasanthanathan Poongavanam,et al.  A comparative study of binding affinities for 6,7-dimethoxy-4-pyrrolidylquinazolines as phosphodiesterase 10A inhibitors using the linear interaction energy method. , 2015, Journal of molecular graphics & modelling.

[8]  P. Cole,et al.  Mechanism and inhibition of cytochrome P-450 aromatase. , 1990, Journal of medicinal chemistry.

[9]  Chris Oostenbrink,et al.  Improved ligand-protein binding affinity predictions using multiple binding modes. , 2010, Biophysical journal.

[10]  David Baker,et al.  PROTEINS: Structure, Function, and Bioinformatics 58:893–904 (2005) A “Solvated Rotamer ” Approach to Modeling Water- Mediated Hydrogen Bonds at Protein–Protein Interfaces , 2022 .

[11]  A. Brodie Aromatase inhibitors in breast cancer , 2002, Trends in Endocrinology & Metabolism.

[12]  Pramod C. Nair,et al.  An Automated Force Field Topology Builder (ATB) and Repository: Version 1.0. , 2011, Journal of chemical theory and computation.

[13]  Chartchalerm Isarankura-Na-Ayudhya,et al.  Molecular Docking of Aromatase Inhibitors , 2011, Molecules.

[14]  Chris Oostenbrink,et al.  CYP 2D6 Binding Affinity Predictions Using Multiple Ligand and Protein Conformations , 2013, International journal of molecular sciences.

[15]  G. Klebe Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.

[16]  R. Santen,et al.  Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer , 1995, Cancer.

[17]  Nico P E Vermeulen,et al.  Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method. , 2004, Journal of medicinal chemistry.

[18]  Sebastian Schmidt,et al.  Hands-off Linear Interaction Energy Approach to Binding Mode and Affinity Estimation of Estrogens , 2013, J. Chem. Inf. Model..

[19]  Daan P. Geerke,et al.  Towards Automated Binding Affinity Prediction Using an Iterative Linear Interaction Energy Approach , 2014, International journal of molecular sciences.

[20]  Berk Hess,et al.  Improving efficiency of large time‐scale molecular dynamics simulations of hydrogen‐rich systems , 1999, Journal of computational chemistry.

[21]  J. Sridhar,et al.  Insights on Cytochrome P450 Enzymes and Inhibitors Obtained Through QSAR Studies , 2012, Molecules.

[22]  Ming Yan,et al.  Discovery of novel aromatase inhibitors using a homogeneous time-resolved fluorescence assay , 2014, Acta Pharmacologica Sinica.

[23]  Shagufta,et al.  Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer. , 2015, European journal of medicinal chemistry.

[24]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[25]  Chris Oostenbrink,et al.  Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450 , 2008 .

[26]  G. McGaughey,et al.  pi-Stacking interactions. Alive and well in proteins. , 1998, The Journal of biological chemistry.

[27]  A. Cavalli,et al.  A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. , 2001, Journal of medicinal chemistry.

[28]  W. Boon,et al.  Aromatase--a brief overview. , 2002, Annual review of physiology.

[29]  R. Brueggemeier,et al.  Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[30]  Takako Sakamoto,et al.  Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells. , 2010, The Journal of nutritional biochemistry.

[31]  M. Dowsett,et al.  ARIMIDEX™: A new oral, once-a-day aromatase inhibitor , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  Andreas P. Eichenberger,et al.  Definition and testing of the GROMOS force-field versions 54A7 and 54B7 , 2011, European Biophysics Journal.

[33]  F. Guengerich,et al.  Cytochrome P450s and other enzymes in drug metabolism and toxicity , 2006, The AAPS Journal.

[34]  H. Berendsen,et al.  Interaction Models for Water in Relation to Protein Hydration , 1981 .

[35]  C. Laughton,et al.  Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. , 1996, Cancer research.

[36]  Shiuan Chen,et al.  Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. , 2006, Cancer research.

[37]  Sean Ekins,et al.  Pharmacophore modeling of cytochromes P450. , 2002, Advanced drug delivery reviews.

[38]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[39]  Thomas Stützle,et al.  An ant colony optimization approach to flexible protein–ligand docking , 2007, Swarm Intelligence.

[40]  Daan P. Geerke,et al.  Linear Interaction Energy Based Prediction of Cytochrome P450 1A2 Binding Affinities with Reliability Estimation , 2015, PloS one.

[41]  R. Elledge,et al.  Oestrogen receptors and breast cancer , 1997, BMJ.

[42]  Chris Oostenbrink,et al.  Are Automated Molecular Dynamics Simulations and Binding Free Energy Calculations Realistic Tools in Lead Optimization? An Evaluation of the Linear Interaction Energy (LIE) Method , 2006, J. Chem. Inf. Model..

[43]  V. Njar,et al.  Aromatase inhibitors and their application in breast cancer treatment☆ , 2000, Steroids.

[44]  A. Cavalli,et al.  Nonsteroidal aromatase inhibitors: Recent advances , 2002, Medicinal research reviews.

[45]  Jur P. van den Berg,et al.  A method to obtain a near‐minimal‐volume molecular simulation of a macromolecule, using periodic boundary conditions and rotational constraints , 2004, J. Comput. Chem..

[46]  C. Osborne,et al.  Steroid hormone receptors in breast cancer management , 2004, Breast Cancer Research and Treatment.

[47]  J. Aqvist,et al.  A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.

[48]  J. Åqvist,et al.  Ligand binding affinities from MD simulations. , 2002, Accounts of chemical research.

[49]  Paulo Augusto Netz,et al.  Linear interaction energy (LIE) method in lead discovery and optimization. , 2008, Current drug targets.

[50]  Emilio Gallicchio,et al.  Linear Interaction Energy (LIE) Models for Ligand Binding in Implicit Solvent:  Theory and Application to the Binding of NNRTIs to HIV-1 Reverse Transcriptase. , 2007, Journal of chemical theory and computation.

[51]  R. Santen,et al.  Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. , 1982, Annals of internal medicine.

[52]  S. P. Lloyd,et al.  Least squares quantization in PCM , 1982, IEEE Trans. Inf. Theory.

[53]  Jozef Hritz,et al.  Efficient free energy calculations for compounds with multiple stable conformations separated by high energy barriers. , 2009, The journal of physical chemistry. B.

[54]  A. Eisen,et al.  Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. , 2008, Cancer treatment reviews.

[55]  R. Santen,et al.  Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. , 1978, The Journal of clinical endocrinology and metabolism.

[56]  E. J. Tavares da Silva,et al.  Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation. , 2005, Journal of medicinal chemistry.

[57]  David L Mobley,et al.  Alchemical free energy methods for drug discovery: progress and challenges. , 2011, Current opinion in structural biology.

[58]  Yongjun Wang,et al.  Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction , 2008, J. Comput. Aided Mol. Des..

[59]  D. Flockhart,et al.  Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro , 2009, Cancer Chemotherapy and Pharmacology.

[60]  J. Jackson,et al.  Safety issues surrounding the use of aromatase inhibitors in breast cancer , 2003, Expert opinion on drug safety.

[61]  Christine M. Bathelt,et al.  Quantum Mechanics/Molecular Mechanics Modeling of Regioselectivity of Drug Metabolism in Cytochrome P450 2C9 , 2013, Journal of the American Chemical Society.

[62]  Wilfred F. van Gunsteren,et al.  A generalized reaction field method for molecular dynamics simulations , 1995 .

[63]  N. Teixeira,et al.  Synthesis and biochemical studies of 17-substituted androst-3-enes and 3,4-epoxyandrostanes as aromatase inhibitors , 2008, Steroids.

[64]  C. Nantasenamat,et al.  Probing the origins of aromatase inhibitory activity of disubstituted coumarins via QSAR and molecular docking , 2014, EXCLI Journal : Experimental and Clinical Sciences.

[65]  W. Pangborn,et al.  Structural basis for androgen specificity and oestrogen synthesis in human aromatase , 2009, Nature.

[66]  D. A. Dougherty,et al.  Cation-pi interactions in structural biology. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Thompson Ea,et al.  Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. , 1974 .

[68]  Williams E. Miranda,et al.  Improving the LIE Method for Binding Free Energy Calculations of Protein-Ligand Complexes , 2015, J. Chem. Inf. Model..

[69]  C. Osborne,et al.  Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. , 1999, Endocrine-related cancer.

[70]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[71]  TSJERK A. WASSENAAR,et al.  The effect of box shape on the dynamic properties of proteins simulated under periodic boundary conditions , 2006, J. Comput. Chem..

[72]  J. Kellis,et al.  Purification and characterization of human placental aromatase cytochrome P-450. , 1987, The Journal of biological chemistry.

[73]  Eric Westhof,et al.  Halogen bonds in biological molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Angelo Carotti,et al.  Three‐dimensional model of the human aromatase enzyme and density functional parameterization of the iron‐containing protoporphyrin IX for a molecular dynamics study of heme‐cysteinato cytochromes , 2006, Proteins.

[75]  U. Dwivedi,et al.  Molecular docking and 3D-QSAR-based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer , 2015, Journal of biomolecular structure & dynamics.

[76]  R. Brueggemeier,et al.  Aromatase inhibitors in the treatment of breast cancer. , 2005, Endocrine reviews.

[77]  G. McLachlan,et al.  The EM Algorithm and Extensions: Second Edition , 2008 .

[78]  H. Adlercreutz,et al.  Aromatase inhibitor development for treatment of breast cancer , 2004, Breast Cancer Research and Treatment.

[79]  E. Baker,et al.  Hydrogen bonding in globular proteins. , 1984, Progress in biophysics and molecular biology.

[80]  Michael R. Shirts,et al.  Extremely precise free energy calculations of amino acid side chain analogs: Comparison of common molecular mechanics force fields for proteins , 2003 .

[81]  W. L. Jorgensen,et al.  AN EXTENDED LINEAR RESPONSE METHOD FOR DETERMINING FREE ENERGIES OF HYDRATION , 1995 .

[82]  Johan Åqvist,et al.  Ligand binding affinity prediction by linear interaction energy methods , 1998, J. Comput. Aided Mol. Des..

[83]  Udayan Dutta,et al.  Aromatase inhibitors: past, present and future in breast cancer therapy , 2008, Medical oncology.

[84]  R. Galeazzi,et al.  Insight into the binding interactions of CYP450 aromatase inhibitors with their target enzyme: a combined molecular docking and molecular dynamics study , 2012, Journal of Molecular Modeling.

[85]  Yate-Ching Yuan,et al.  Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. , 2007, Molecular endocrinology.

[86]  W. Pangborn,et al.  X-ray structure of human aromatase reveals an androgen-specific active site , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[87]  P. Graves,et al.  Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide. , 1979, Endocrinology.

[88]  Andreas Bender,et al.  Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms , 2012, J. Chem. Inf. Model..

[89]  D. Sundar,et al.  Insight into the Enzyme-Inhibitor Interactions of the First Experimentally Determined Human Aromatase , 2011, Journal of biomolecular structure & dynamics.

[90]  D. Covey,et al.  Effects of steroid D-ring modification on suicide inactivation and competitive inhibition of aromatase by analogues of androsta-1,4-diene-3,17-dione. , 1989, Journal of medicinal chemistry.

[91]  D. Tripathy,et al.  Aromatase inhibitors: rationale and use in breast cancer. , 2005, Annual review of medicine.

[92]  B Testa,et al.  In silico pharmacology for drug discovery: applications to targets and beyond , 2007, British journal of pharmacology.

[93]  J. Thornton,et al.  Ion-pairs in proteins. , 1983, Journal of molecular biology.

[94]  C. Watson,et al.  Regulation of aromatase activity within the breast , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[95]  Gerhard Wolber,et al.  Molecular dynamics simulation and linear interaction energy study of d-Glu-based inhibitors of the MurD ligase , 2013, Journal of Computer-Aided Molecular Design.

[96]  Giulio Rastelli,et al.  Advances and applications of binding affinity prediction methods in drug discovery. , 2012, Biotechnology advances.

[97]  Alexandre M J J Bonvin,et al.  A Flexible, Grid-Enabled Web Portal for GROMACS Molecular Dynamics Simulations. , 2012, Journal of chemical theory and computation.

[98]  Thomas Stützle,et al.  Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..

[99]  Hugo Gutiérrez-de-Terán,et al.  Linear interaction energy: method and applications in drug design. , 2012, Methods in molecular biology.

[100]  Victor Guallar,et al.  Peripheral heme substituents control the hydrogen-atom abstraction chemistry in cytochromes P450 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[101]  Jens Carlsson,et al.  Improving the Accuracy of the Linear Interaction Energy Method for Solvation Free Energies. , 2007, Journal of chemical theory and computation.

[102]  J L Kelsey,et al.  Reproductive factors and breast cancer. , 1993, Epidemiologic reviews.

[103]  K. Wähälä,et al.  The binding of lignans, flavonoids and coumestrol to CYP450 aromatase: A molecular modelling study , 2009, Molecular and Cellular Endocrinology.